NCT00655330

Probucol Combined With Valsartan in Reducing Proteinuria in Diabetes Nephropathy

A Prospective Randomized, Controlled, Open-labeled Trial of Probucol Combined With Valsartan in Patients With Diabetes Nephropathy

• Status: Unknown
• Phase: N/A
• Study type: Interventional
• Enrollment: 170 (estimated)
• Sponsor: Guangdong Provincial People's Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

This is a prospective randomized controlled, open-labeled study to identify the efficacy of probucol in combination with valsartan in patients with Diabetes nephropathy. The reduction of urinary albumin or proteinuria will be the primary outcome studied. The expected study duration will be 48 weeks.

Detailed description

a prospective randomized controlled, open-labeled study in patients with Diabetes nephropathy * Arm 1: Valsartan + Probucol Valsartan (160mg/day) + Probucol (750mg/day) * Arm 2: Valsartan + Placebo Valsartan (160mg/day) + Placebo

Conditions

• Type 2 Diabetes Mellitus
• Nephropathy

Interventions

Type	Name	Description
DRUG	Valsartan	Valsartan (160mg/day)
DRUG	Placebo	Placebo
DRUG	Probucol	Probucol (750mg/day)

Timeline

• Start date: 2008-05-01
• Primary completion: 2017-05-01
• Completion: 2017-05-01
• First posted: 2008-04-09
• Last updated: 2016-08-24

Locations

1 site across 1 country: China